Advisor
Thomas F. Delaney, M.D. is a graduate of Harvard College and Harvard Medical School. Following internship in General Surgery at Yale-New Haven Hospital, he trained in Radiation Oncology at the Massachusetts General Hospital (MGH) followed by 6 years as a Senior Investigator at the U.S. National Cancer Institute. From 1992 to 2021, he was on the staff/faculty at MGH and Harvard Medical School (HMS). He was Medical Director of the Burr Proton Therapy Center at MGH from 2001-2018, Co-Director of the Sarcoma Center at MGH from 2000-2021, and Andres Soriano Professor of Radiation Oncology (HMS) from 2013-2021. He is a Fellow of the American Society for Radiation Oncology (ASTRO).
He has served on the Executive Board of the Connective Tissue Oncology Society, the NCCN Soft Tissue Sarcoma Guidelines Panel, and on the Medical Advisory Board of the Chordoma Foundation. He led the NRG Oncology Proton Clinical Trials Working Group from 2005-2021 and was an active member of the NRG Oncology Sarcoma Working Group from 2000-2021.
Dr. DeLaney is active in sarcoma and proton radiation clinical research. He was the principal investigator of NCI-funded P01 and U19 proton therapy grants from 2005-2016. His curriculum vitae lists over 175 original reports as well as over 100 reviews, book chapters, editorials, and clinical guidelines. He co-edited the books, Proton and Charged Particle Radiotherapy (2007) and Sarcomas: Evidence-Based Diagnosis and Management (2020) . He has served on the editorial boards of the Journal of Surgical Oncology, Annals of Surgical Oncology, Journal of Clinical Oncology, and UpToDate in Oncology.